AUS
NZ
UK
CA
USA
IND
_06_27_2025_01_29_51_988272.jpg)
Highlights
Genflow Biosciences PLC (LON:GENF) prepares lead therapy GF-1002 for clinical trial authorisation
Collaborates with Exothera to meet quality manufacturing standards
Secures regional support from Belgium to boost longevity research pipeline
Genflow Biosciences PLC, listed on the ftse, ftse aim 100 index, and ftse aim uk 50 index, under ticker (LON:GENF), is a United Kingdom-based biotechnology company pioneering work in the field of aging and age-associated disorders. The company’s approach centers on gene therapies designed to delay or reduce the onset of conditions commonly associated with advanced age.
Using adeno-associated virus (AAV) vectors, Genflow aims to deliver copies of a unique variant of the Sirtuin-6 (SIRT6) gene, found in individuals with exceptional longevity. These gene therapies are intended to support healthier cellular function and extend biological healthspan.
GF-1002 advances towards clinical trials
Genflow Biosciences continues advancing its primary gene therapy candidate, GF-1002, toward clinical trial authorisation in Europe. This step is a critical part of the regulatory process required before beginning studies involving human participants. The company is working in collaboration with Exothera, a specialised manufacturing partner, to ensure that production protocols meet stringent quality and safety regulations in line with good manufacturing practice (GMP) standards.
These measures aim to guarantee consistency, quality, and safety in the gene therapy's formulation, a necessary aspect before entering any trial phases.
Belgium support strengthens development pipeline
Furthering its development goals, Genflow has received significant backing from the Wallonia region of Belgium. This support will be used to advance GF-1002 as part of a multi-year plan aimed at addressing metabolic-associated steatohepatitis (MASH). This strategic alignment fits into the company’s broader roadmap and timeline, with funding aiding research, development, and production capabilities for the programme.
This regional partnership underlines Genflow’s collaborative efforts within Europe to develop gene therapies that can address some of the most complex biological challenges related to aging.
Continued pipeline expansion and scientific progress
In addition to GF-1002, Genflow reported broader momentum across its pipeline, which also includes programmes targeting muscle degeneration and vision-related disorders linked to aging. The company has made progress in both scientific research and intellectual property, aiming to safeguard its technology while expanding applications across various indications.
Collaborations with research institutions and strategic stakeholders have been instrumental in sustaining this development. The company has indicated a consistent drive toward moving its therapies from pre-clinical to clinical phases, supported by ongoing laboratory outcomes and scalable manufacturing strategies.
Genflow’s continued evolution in this specialised biotech field reinforces its positioning as a European innovator in addressing age-associated biological decline through genetic science.
